Get started
Inovio Pharmaceuticals, Inc.Inovio Pharmaceuticals, Inc.Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

INO chart


Full chart

INO upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪59.04 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.98 USD
Net income (FY)
‪−107.25 M‬ USD
Revenue (FY)
‪217.76 K‬ USD
Shares float
‪36.42 M‬
Beta (1Y)
1.66

Employees


Employees (FY)
134
Change (1Y)
+12 +9.84%
Revenue / Employee (1Y)
‪1.63 K‬ USD
Net income / Employee (1Y)
‪−800.40 K‬ USD

About Inovio Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Jacqueline E. Shea
Website
inovio.com
Headquarters
Plymouth Meeting
Founded
1983
FIGI
BBG000BK6YX5
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

INO news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as INO.

Frequently Asked Questions


The current price of INO is 1.75 USD — it has increased by 9.94% in the past 24 hours. Watch Inovio Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Inovio Pharmaceuticals, Inc. stocks are traded under the ticker INO.
INO stock has risen by 18.00% compared to the previous week, the month change is a −10.61% fall, over the last year Inovio Pharmaceuticals, Inc. has showed a −84.09% decrease.
We've gathered analysts' opinions on Inovio Pharmaceuticals, Inc. future price: according to them, INO price has a max estimate of 15.00 USD and a min estimate of 2.00 USD. Watch INO chart and read a more detailed Inovio Pharmaceuticals, Inc. stock forecast: see what analysts think of Inovio Pharmaceuticals, Inc. and suggest that you do with its stocks.
INO reached its all-time high on Mar 6, 2000 with the price of 2,352.00 USD, and its all-time low was 1.42 USD and was reached on Apr 9, 2025. View more price dynamics on INO chart.
See other stocks reaching their highest and lowest prices.
INO stock is 6.17% volatile and has beta coefficient of 1.66. Track Inovio Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Inovio Pharmaceuticals, Inc. there?
Today Inovio Pharmaceuticals, Inc. has the market capitalization of ‪64.91 M‬, it has increased by 5.33% over the last week.
Yes, you can track Inovio Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Inovio Pharmaceuticals, Inc. is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
INO earnings for the last quarter are −0.65 USD per share, whereas the estimation was −0.84 USD resulting in a 22.34% surprise. The estimated earnings for the next quarter are −0.69 USD per share. See more details about Inovio Pharmaceuticals, Inc. earnings.
Inovio Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪117.00 K‬ USD, despite the estimated figure of ‪40.00 K‬ USD. In the next quarter, revenue is expected to reach ‪12.50 K‬ USD.
INO net income for the last quarter is ‪−19.38 M‬ USD, while the quarter before that showed ‪−25.17 M‬ USD of net income which accounts for 22.98% change. Track more Inovio Pharmaceuticals, Inc. financial stats to get the full picture.
No, INO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 134 employees. See our rating of the largest employees — is Inovio Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Inovio Pharmaceuticals, Inc. EBITDA is ‪−109.27 M‬ USD, and current EBITDA margin is ‪−50.91 K‬%. See more stats in Inovio Pharmaceuticals, Inc. financial statements.
Like other stocks, INO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Inovio Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Inovio Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Inovio Pharmaceuticals, Inc. stock shows the sell signal. See more of Inovio Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.